MabVax Therapeutics Lines Up $3.7M Ch. 11 Asset Sale
After a last-minute negotiating flurry, biotech firm MabVax Therapeutics Holdings secured tentative approval Monday for the $3.7 million sale of many of its remaining assets while retaining litigation rights against alleged...To view the full article, register now.
Already a subscriber? Click here to view full article